Preclinical research from The University of Texas MD Anderson Cancer Center finds that although glioblastoma stem cells (GSCs) can be targeted by natural killer (NK) cells, they are able to evade immune attack by releasing the TFG-β signaling protein, which blocks NK cell activity. Deleting the TFG-β receptor in NK cells, however, rendered them resistant to this immune suppression and enabled their anti-tumor activity.
The findings...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic...
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer. The findings for each cohort were published today in The Lancet Oncology and...
ABSTRACT #9003
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib...
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel function for the metabolic enzyme medium-chain acyl-CoA...
Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for...
The University of Texas MD Anderson Cancer Center has united with fellow National Cancer Institute (NCI)-Designated Cancer Centers and partner...
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind artificial intelligence (AI)-based tool...
Today, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded The University of Texas MD Anderson Cancer Center $4 million...